about
Parasitic diseases of the central nervous system: lessons for clinicians and policy makers.Cysticercosis and epilepsy: a critical review.Neurocysticercosis and epilepsy in developing countries.Seizure in people with newly diagnosed active or transitional neurocysticercosis.Neurocysticercosis: an update.Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?The relationship between neurocysticercosis and epilepsy: an endless debate.The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis.Validity of a PCR assay in CSF for the diagnosis of neurocysticercosis.New diagnostic criteria for neurocysticercosis: Reliability and validity.Undue regulatory control on phenobarbital--an important yet overlooked reason for the epilepsy treatment gap.Epilepsy in the developing world.Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.What proportion of cases of epilepsy are actually caused by neurocysticercosis?Reciprocal contribution of clinical studies and the HP10 antigen ELISA for the diagnosis of extraparenchymal neurocysticercosis.The primary prevention of epilepsy: A report of the Prevention Task Force of the International League Against Epilepsy.The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.Neurocysticercosis: the good, the bad, and the missing.Reproducibility of Diagnostic Criteria for Ventricular Neurocysticercosis.State of the art in neurocysticercosis: Imaging and epidemiology.Investigation of familial aggregation of seizures in neurocysticercosis patientsA modified lateral flow assay, using serum, for the rapid identification of human and bovine cysticercosis in the absence of false positivesReplyReplyCombined antiparasitic treatment for neurocysticercosisMultifactorial basis of epilepsy in patients with neurocysticercosisShould calcified neurocysticercosis lesions be surgically removed?Taenia solium seropositivity in patients with active epilepsyComparison of complementary diagnostic tests in cerebrospinal fluid and serum for neurocysticercosisMonitoring treatment of Taenia solium- neurocysticercosis by detection of circulating antigens: a case reportIs the course of neurocysticercosis modified by treatment with antihelminthic agents?A proposal for classification of neurocysticercosisDiagnostic criteria for human cysticercosisNew guidelines for the diagnosis and treatment of neurocysticercosis: a difficult proposal for patients in endemic countriesExploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis
P50
Q28077177-E50BBEF3-1D65-4B80-A53C-3EFF8BAA1040Q31997730-C8EEE473-EFB0-454F-97CF-53BEF823B75EQ33822596-2FDA77C6-B72A-4F4F-B931-E591FEF948E1Q34675034-64EABF4C-3BF4-43E2-9B1A-BB50EB8412BEQ35017750-963836BE-BD1E-4BC0-9D2B-608838B88FADQ38180096-82C7B39A-F8F3-47DA-8772-A6002D927838Q38215122-B5A466B6-BF9F-4EF7-8E6E-8A67D1C55450Q38957137-8C69F049-D371-4A76-8510-CB9E81236DCDQ40372284-159141DE-E329-4D6C-96AD-19F339BC1AF5Q41349963-6755FBEE-FA73-445D-A915-91C6485130BFQ43581122-191CB1E9-B501-49D2-A1D9-01DC0B40F9DCQ45974518-6A8FA62C-53FB-4C37-BABE-A605F22724C8Q46582540-56BC2B32-BCAF-4E12-9EC4-89A28FA8F272Q48180954-324AF35E-459F-4FB2-AE90-F2677C488B46Q49861626-A370D46F-5548-4897-B1BA-BE590AFF1A5DQ52594717-16B1270F-14B8-46F5-B7E5-033A070C1066Q52630982-8DFC3BE5-BC70-4CDD-A85A-748C75F0308EQ52665173-F4BE42D8-7326-4A3F-9808-FCA8371C2774Q52765340-EFDAA4FC-D6B7-4EE9-8335-68029D6CC553Q54453511-E3B47D62-A148-4FBF-AD68-5A9CB657C8F3Q57215549-2EF5A9A8-719C-4953-BF12-3452C10B0B43Q58085531-5137378B-932E-4FB0-9DEE-0872DD997C4CQ58484124-0E8AE74B-7E67-4832-A0B6-BF2E90DCCE1AQ58484127-03E24EBC-91A2-4D81-9A40-5098003775EDQ58484128-29F0670F-E801-45FB-B6AE-18C9748EC469Q58484130-D83F80E4-268D-4D06-813C-3D863BE00897Q58484133-A369D7CD-25FE-42A4-8E72-70D3DCB2A886Q58484134-115F60EA-35C7-4770-AF96-C7FD30B18300Q59797243-2BF0B0BA-7E2A-4DB8-8563-7454E4821606Q64078976-35278DF6-5CE8-4181-849B-4C010644636DQ71779709-9BF60BE8-1D6C-4B5A-B86F-8A52D522BCD7Q72414641-4C221535-2A8A-49D0-B775-D031F848D0E7Q77763624-7D2C7E21-8A35-4BBB-85CC-2133F8C7DFF1Q91301481-0A4DAF9C-F6FB-4670-A526-ED0A26746A89Q92247817-4EB3DB6E-05B8-4AD8-A87F-CE7401941670
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5821-6379
@en
name
Arturo Carpio
@ast
Arturo Carpio
@en
Arturo Carpio
@es
Arturo Carpio
@nl
type
label
Arturo Carpio
@ast
Arturo Carpio
@en
Arturo Carpio
@es
Arturo Carpio
@nl
prefLabel
Arturo Carpio
@ast
Arturo Carpio
@en
Arturo Carpio
@es
Arturo Carpio
@nl
P106
P21
P31
P496
0000-0002-5821-6379